LYVE1 and breast cancer: Collectively, these data show that the majority of M2-type TAMs in BC models including fusogenic Lyve-1+ myeloid cells (Figure 1, Figure 2, Figure 3, Figure 4 and Figure 5) are derived from the bone marrow and that a substantial portion of tumor lymphatic vessels undergo fusion.